Relevant bibliographies by topics / Chronic Hepatitis C (CHC)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Chronic Hepatitis C (CHC)'

Author: Grafiati
Published: 3 June 2025
Last updated: 23 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chronic Hepatitis C (CHC).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Chronic Hepatitis C (CHC)"

1

Tkachenko, L. I., and V. V. Maleev. "Insulin resistance and chronic hepatitis C." Terapevticheskii arkhiv 88, no. 11 (2016): 29–36. http://dx.doi.org/10.17116/terarkh2016881129-36.

Full text
Abstract:
Aim. To estimate the spread of insulin resistance (IR) in patients with chronic hepatitis C (CHC) and to define the role of IR in the development of hepatic steatosis (HS) and in the progression of liver fibrosis (LF), as well as the impact of IR on the results of antiviral therapy (AVT). Subjects and methods. A total of 211 patients with CHC were examined. A comparison group consisted of 75 patients with chronic hepatitis B (CHB). The patients were divided according to the presence and absence of IR and type 2 diabetes mellitus (DM). IR was analyzed in patients with CHC with a body mass index (BMI) of
APA, Harvard, Vancouver, ISO, and other styles
2

Abdikerimova, M. M. "PREGNANCY AND CHILDBIRTH COURSE PECUARITIES IN WOMEN SUFFERING FROM CHRONIC VIRAL HEPATITIS." Hepatology and Gastroenterology 8, no. 1 (2024): 31–35. http://dx.doi.org/10.25298/2616-5546-2024-8-1-31-35.

Full text
Abstract:
Background. Chronic viral hepatitis (CVH) B and C are considered socially significant infections. More than 290 million people worldwide live with chronic hepatitis B (CHB) and more than 58 million have been infected with hepatitis C virus (HCV). Every year, about 1.5 million people become newly infected. In recent years, chronic hepatitis has occupied one of the leading places in the structure of extragenital pathology in pregnant women. Objective. To evaluate the characteristics of pregnancy and childbirth course in women with CHB, CHC and CHB+СHC. Material and methods. The paper presents the results of a retrospective analysis of 141 individual records of pregnant women with CHB, CHC and CHB+СHC and their birth histories. The average age of pregnant women was 25.1±3.72 years. Results. CHB, CHC and CHB+СHC negatively affect the course of pregnancy: the threat of miscarriage and the frequency of gestosis increase, chronic fetoplacental insufficiency and polyhydramnios are more often detected, premature birth occurs as well. Childbirth in pregnant women with chronic hepatitis is accompanied by the development of complications: hypotonic uterine contractions, premature rupture of membranes. Chronic HCV-infection causes more serious metabolic changes than HBV, which significantly complicate the course of pregnancy and childbirth. Conclusions. CHB, CHC and CHB+СHC negatively affect the course of pregnancy and childbirth.
APA, Harvard, Vancouver, ISO, and other styles
3

Loosen, Sven H., Alexander Killer, Hans Henrich Bock, Tom Luedde, Christoph Roderburg, and Karel Kostev. "Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study." Journal of Clinical Medicine 13, no. 20 (2024): 6152. http://dx.doi.org/10.3390/jcm13206152.

Full text
Abstract:
Background: Osteoporosis and bone fractures affect health and quality of life. Since bone disease is multifactorial, identifying risk factors is key in prevention. There are multiple reports on how viral hepatitis, especially chronic hepatitis B (CHB) and chronic hepatitis C (CHC), are affecting bone disease, but results vary. Here, we analyzed the potential association between CHB/CHC and osteoporosis or bone fractures in a large outpatient cohort in Germany. Methods: We included 3136 outpatients with CHB and 15,608 matched non-hepatitis individuals as well as 2867 outpatients with CHC and 14,335 matched non-hepatitis individuals from the Disease Analyzer Database between 2005 and 2022. The main outcome was the 5-year cumulative incidence of osteoporosis and bone fractures as a function of either CHB or CHC. Results: Within 5 years of the index date, 2.9% vs. 1.6% of patients with and without CHB were diagnosed with osteoporosis (p = 0.001) and 1.0% vs. 0.4% were diagnosed with bone fractures (p < 0.001). Moreover, 3.3% of CHC patients and 2.2% of individuals without hepatitis C were diagnosed with osteoporosis (p = 0.002). In Cox regression analyses, CHB was significantly associated with an increased risk for osteoporosis (HR: 1.76) and fractures (HR:2.43) and CHC with osteoporosis (HR: 1.54). For both CHB and CHC, the association with osteoporosis was restricted to the female subgroup. Conclusions: CHB and CHC are associated with osteoporosis in women. CHB in male patients is associated with a higher risk of fractures. More research is needed to understand the underlying pathophysiological mechanisms.
APA, Harvard, Vancouver, ISO, and other styles
4

Malghani, Waseem Sarwar, Farooq Mohyud Din Chaudhary, Muhammad Ali Wadhak, Asma Tameez Ud Din, Anum Khakwani, and Asim Tameez Ud Din. "CHRONIC HEPATITIS C." Professional Medical Journal 25, no. 06 (2018): 860–64. http://dx.doi.org/10.29309/tpmj/2018.25.06.271.

Full text
Abstract:
Background: Pegylated interferon (PEG-IFN) plus ribavirin combination was themain treatment for chronic hepatitis C (CHC) patients in Pakistan till 2016. An important sideeffect of this combination was thyroid dysfunction (TD). Objectives: To evaluate thyroid functionabnormalities in Chronic Hepatitis C patients treated with PEG-IFN and ribavirin. Study Design:Descriptive study. Setting: Outpatient Department of Gastroenterology and Hepatology,Nishtar Hospital Multan. Period: January to September 2016. Methods: Using non-probabilityconsecutive sampling. There were 337 CHC patients enrolled in the study who fulfilled theinclusion criteria. Patients were given PEG-IFN plus ribavirin combination therapy and at 12weeks their serum Thyroid Stimulating Hormone (TSH) levels were measured to identify any TD.Data was entered and analyzed by computer program SPSS-17. Results: Of these 337 cases,211 (62.6%) were male patients while 126 (37.4%) were female patients. Mean age of our caseswas noted to be 30.92 ± 5.84 years. Mean disease duration was 16.19 ± 6.42 months. In ourstudy 98 patients (29.1%) had genotype 2 while 239 (70.9%) had genotype 3. TD was seenin 28 (8.3%) patients, 70% of whom were females. Equal number of cases of Hypothyroidismand hyperthyroidism were seen (14 each). Hypothyroidism was significantly associated withrelatively older age group patients and genotype 3 (p value <0.05). A statistically significantassociation (p<0.05) was found between hyperthyroidism and genotype 3, female gender andyounger patients. Conclusion: PEG-IFN plus ribavirin combination therapy induces TD amongpatients with CHC with equal incidence of hypothyroidism and hyperthyroidism.
APA, Harvard, Vancouver, ISO, and other styles
5

Abdikerimova, M., A. Kanatbekova, and M. Abdikerimov. "Concomitant Diseases in Pregnant Women Suffering with Chronic Viral Hepatitis B and C." Bulletin of Science and Practice 10, no. 8 (2024): 247–53. http://dx.doi.org/10.33619/2414-2948/105/28.

Full text
Abstract:
The work identified concomitant diseases in 120 pregnant women suffering from chronic viral hepatitis B and C (CHB and CHC), aged 19 to 30 years. In the structure of extragenital pathology, the largest percentage belongs to diseases of the gastrointestinal tract, which was detected in 71.0% of 69 patients with CHB, in 76.5% of 51 pregnant women with CHC and in 42.1% of 57 relatively healthy pregnant women. Among the nosological forms were mainly chronic gastritis, chronic gastroduodenitis, biliary dyskinesia and chronic pancreatitis. Chronic viral hepatitis in pregnant women determines a high incidence of gastrointestinal tract damage due to biliary dyskinesia, apparently associated with viral liver damage. Urogenital infections among pregnant women are significantly more common in patients with CHB (59.4%) and CHC (80.3%) (p <0.05) than in those without liver pathology (21.5%). Among the urogenital infections, the most common was a combination of chlamydia and candidiasis, and less frequently, trichomonas infection, and only one patient was diagnosed with syphilis. Chronic viral hepatitis is a factor contributing to the development of urogenital infection in pregnant women.
APA, Harvard, Vancouver, ISO, and other styles
6

Sobhy, Ali, Mohammed Fakhry M., Haitham A Azeem, Ahmed M. Ashmawy, and Hamed Omar Khalifa. "Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus." Journal of Investigative Medicine 67, no. 3 (2018): 681–85. http://dx.doi.org/10.1136/jim-2018-000840.

Full text
Abstract:
Several studies were performed to evaluate the degree of liver fibrosis by non-invasive markers. We aimed to assess the diagnostic value of both biglycan (BGN) and osteopontin (OPN) as non-invasive markers of hepatic fibrosis in patients with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). This study was performed on 100 patients with CHB virus, 100 patients with CHC virus and 100 normal controls. All participants were subjected to the following laboratory tests: hemoglobin, platelet, alanine aminotransferase, aspartate aminotransferase, albumin, international normalized ratio, HBs Ag, hepatitis C virus (HCV) antibody, hepatitis B virus DNA, HCV RNA, liver biopsy, BGN and OPN. We found that BGN level was significantly increased in the CHB group compared with the controls (p<0.001), but the level was not different between the CHC group and the controls (p<0.96). OPN was increased in both the CHB and CHC groups compared with the controls (p<0.001). Positive correlation was found between fibrosis stages and BGN level of the CHB group (r=0.64; p<0.001) and between fibrosis stages and OPN level of the CHB (r=0.63; p<0.001) and CHC (r=0.59; p<0.03) groups. The area under the curve (AUC), sensitivity and specificity of BGN were 1.0, 100% and 100% in predicting fibrosis in patients with CHB, and 0.50, 26% and 78% in predicting fibrosis in patients with CHC. OPN had an AUC of 0.997, sensitivity of 96% and specificity of 100% in predicting fibrosis in patients with CHB, and 0.974, 96.5% and 100% in predicting fibrosis in patients with CHC. In conclusion, BGN and OPN could be considered non-invasive markers for liver fibrosis assessment.
APA, Harvard, Vancouver, ISO, and other styles
7

Abdikerimova, M., A. Kanatbekova, M. Abdikerimov, and S. Zholdoshev. "Indicators of Immunological Status in Pregnant Women with Chronic Viral Hepatitis B and C." Bulletin of Science and Practice 10, no. 5 (2024): 342–49. http://dx.doi.org/10.33619/2414-2948/102/43.

Full text
Abstract:
The work presents the results of a study of immunological indicators of cellular and humoral immunity in 45 pregnant women with chronic viral hepatitis B and C. Immunological parameters in pregnant women with CHB and CHC were characterized by suppression of the cellular component of immunity, which is manifested by a decrease in the number of total T-lymphocytes (CD3+), T-helpers (CD4+) and T-suppressors (CD8+), as well as natural killer cells (CD16), which is associated with the mechanism of maintaining pregnancy. Changes in humoral immunity are characterized by a moderate increase in the level of IgG and CEC; in case of CHC, relapse of the disease was also accompanied by an increase in class M immunoglobulins. Chronic viral hepatitis B and C in pregnant women leads to secondary immunodeficiency and an increase in the level of viral replication. A direct correlation has been revealed between indicators of the cellular immune response in CHB and CHC with the level of viral load, which must be taken into account when managing pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
8

Volynets, G. V., and A. I. Khavkin. "Chronic viral hepatitis and inflammatory bowel disease." Voprosy dietologii 11, no. 2 (2021): 29–34. http://dx.doi.org/10.20953/2224-5448-2021-2-29-34.

Full text
Abstract:
The article presents the results of a literature review devoted to the study of the problems of the combined course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), and chronic viral hepatitis (CVH) – chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The frequency of occurrence of CHB and CHC in IBD in different countries is presented, which ranges from 1 to 9%. The clinical course of these combined diseases, the possibility of reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) during immunosuppressive therapy are described. Recommendations on the specifics of examination and management of patients with combined pathology of IBD and CVH are presented. Conclusion. The combined pathology of IBD and CVH is a significant public health problem around the world that requires further large-scale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should be individualized. Key words: inflammatory bowel disease, chronic hepatitis B, chronic hepatitis C, immunosuppressive therapy
APA, Harvard, Vancouver, ISO, and other styles
9

Volynets, G. V. "CHRONIC VIRAL HEPATITIS AND INFLAMMATORY BOWEL DISEASE." Hepatology and Gastroenterology 5, no. 2 (2021): 111–17. http://dx.doi.org/10.25298/2616-5546-2021-5-2-111-117.

Full text
Abstract:
The article presents the results of a literature review devoted to the study of the problems of the concurrent course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), as well as chronic viral hepatitis (CVH) - chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The prevalence of CHB and CHC in IBD in different countries ranges from 1% to 9%. The clinical course of these concurrent diseases, the possibility of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation during immunosuppressive therapy are described. Recommendations on the peculiarities of examination and management of patients with concurrent pathology of IBD and CVH are presented. The combined pathology of IBD and CVH is a significant public health problem worldwide that requires further largescale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should occur on an individual basis.
APA, Harvard, Vancouver, ISO, and other styles
10

Yakovlev, A. A., A. Ya Komarova, V. B. Musatov, et al. "Current trends of the changes of the etiological structure and clinical and laboratory characteristics of hepatocellular carcinoma." Epidemiology and Infectious Diseases 18, no. 6 (2013): 21–27. http://dx.doi.org/10.17816/eid40771.

Full text
Abstract:
The etiological structure of chronic viral hepatitides with the outcome in hepatocellular carcinoma (HCC) was studied among deceased patients for the periods of 1986-1998 and 2002-2012 in total and in comparison. HCC developed as the outcome of CHB in 45.0% of patients, CHC - in 20.7 % , CHB+C - 18,6%, CVHN- in 12.9%, CHB + D - 1.4%, CHB+C+D - also in 1.4% of patients. When comparing the data for 1986-1998 (13 years), and 2002-2012 (11 years) there was noticed an increase in the number of deaths from HCC (2-fold), there was significantly increased the incidence of HCC, associated with CHC (from 2.0% to 30.8 %), nonverified chronic hepatitis as a cause of HCC occurred 6.5 times less often (28.6 % - 4.4%), the number of cases of HCC, caused by CHB, became lower (49.0 % - 42.9 %), CHB+C - almost unchanged (20.4% - 17.6 % ). A presumptive middle time of the development of HCC since infection with hepatitis viruses is 27,6 ± 9,8 years. In assessing the cofactors ofprogression of HCC there was found that alcohol abuse occurred in 38.5 % ofpatients, diabetes - in 18,7%, HIV- infection -in 3.3%.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Chronic Hepatitis C (CHC)"

1

Lim, Teegan Reina. "Metabolic effects of hypoxia and chronic hepatitis C." Thesis, University of Birmingham, 2018. http://etheses.bham.ac.uk//id/eprint/8535/.

Full text
Abstract:
Hypoxia has been linked to the pathogenesis of hepatic steatosis in murine and human models. There is an abundance of data suggesting that HIFs play a central role in regulating hepatic lipid metabolism. This study suggested that hypoxia-induced hepatic lipid accumulation is through de novo lipogenesis and free fatty acid uptake, and is dependent on hypoxia inducible factors la and 2a. On the contrary, hepatitis C infection reduced de novo lipogenesis and free fatty acid uptake in both normoxic and hypoxic conditions in vitro, and this inhibition is viral strain-dependent. In the clinical setting, chronic hepatitis C {CHC) and non-alcoholic fatty liver diseases {NAFLD) are associated with hepatic steatosis and insulin resistance. Using an integrative physiological approach that measures lipid and carbohydrate flux in vivo we demonstrated that patients with CHC had modest increase in insulin resistance and that the relative contribution of tissue specific insulin sensitivity in patients with CHC and NASH varied. Furthermore, curing HCV infection improved hepatic and subcutaneous adipose tissue insulin resistance. The improvement in hepatic and adipose tissue insulin resistance was more pronounced in patients infected with genotype 3 HCV, whilst the improvement in skeletal muscle insulin resistance was more evident in genotype 1 infection, demonstrating a genotype-specific effect in the metabolic perturbation in CHC. Further studies are required to confirm that genotype specific effect of HCV on insulin resistance and its link with NASH.
APA, Harvard, Vancouver, ISO, and other styles
2

Christie, John Michael Landale. "Viral persistence in hepatitis C virus infection." Thesis, University of Southampton, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

HAYASHI, HISAO, TOSHIKUNI TAKlKAWA, KATSUMI KATO, et al. "BIOCHEMICAL IMPROVEMENT OF CHRONIC HEPATITIS C AFTER GASTROINTESTINAL BLEEDING." Nagoya University School of Medicine, 1994. http://hdl.handle.net/2237/16077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Verbaan, Hans. "Chronic hepatitis C infection with special reference to prevalence, aggravating factors and longterm outcome /." Lund : Gastroenterology and Hepatology Division, Dept. of Medicine, University Hospital, Lund University, 1997. http://books.google.com/books?id=SBdrAAAAMAAJ.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hui, Chee-kin, and 許志堅. "Chronic hepatitis C infection: diagnosis, fibrosis progression and interferon therapy." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B29756972.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dolman, Grace E. "Tissue biomarkers of fibrosis progression in chronic hepatitis C infection." Thesis, University of Nottingham, 2016. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.718462.

Full text
Abstract:
Chronic infection with hepatitis C virus leads to liver fibrosis. In some individuals this can progress to cirrhosis and its clinical complications. As such, chronic hepatitis C is a major burden to healthcare systems globally. As fibrosis progression rates are highly variable, it would be useful to be able to identify those individuals at greatest risk of rapid progression. Efficacious therapies for hepatitis C are now available, but are expensive, and will not be available to all. Fibrosis progression is challenging to study due to the long duration of the disease. We have used data from the Trent Study of Patients with Hepatitis C Virus Infection to determine the factors associated with fibrosis progression in patients with advanced fibrosis and cirrhosis. This prospective cohort study contains a wealth of information and has ethical permission to collect clinical outcome data and access a large biobank of liver biopsies. Fibrosis progression is a non-linear process and our data suggest that the factors driving the process may change as fibrosis advances. We describe the development of a semi-automated digital image analysis algorithm to quantify collagen and elastin in archived liver biopsies and we have evaluated these tissue biomarkers as predictors of subsequent clinical outcomes. Elastin shows promise as a novel biomarker of progression to clinical outcomes in liver cirrhosis. Measuring gene expression profiles has the potential to be a sensitive indicator of fibrogenesis, not just fibrosis. We have measured the gene expression profile of archived hepatic biopsy tissue in patients with cirrhosis and we have identified a small number of target genes that have increased expression in those who reach clinical outcomes at 5 years. This work furthers our understanding of the factors that are predictive of progression to clinical outcomes in chronic hepatitis C infection, an area of increasing clinical importance.
APA, Harvard, Vancouver, ISO, and other styles
7

Veldt, Bartholomeus Johannes. "Long-term clinical outcome of treatment for chronic hepatitis C." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/12624.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Abbas, Amro M. "Pathogenesis of disease associated with chronic hepatitis C virus infection." Thesis, University of Nottingham, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.368251.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Carlsson, Tony. "Hepatitis C virus kinetics during antiviral treatment /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-588-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mohamed, Ajayeb Dakhelallah. "The influence of HLA in chronic hepatitis B and C and analysis of a new subtype of hepatitis C virus." Thesis, Imperial College London, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.243795.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Chronic Hepatitis C (CHC)"

1

Ozaras, Resat, and Dominique Salmon-Ceron, eds. Viral Hepatitis: Chronic Hepatitis C. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shiffman, Mitchell L., ed. Chronic Hepatitis C Virus. Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-1192-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

A, Gebo Kelly, United States. Agency for Healthcare Research and Quality., and Johns Hopkins University. Evidence-based Practice Center., eds. Management of chronic hepatitis C. U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) and National Digestive Diseases Information Clearinghouse (U.S.), eds. Chronic hepatitis C: Current disease management. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

National Digestive Diseases Information Clearinghouse (U.S.). Chronic hepatitis C: Current disease management. National Digestive Diseases Information Clearinghouse, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), ed. Chronic hepatitis C: Current disease management. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shih, Chiaho. Chronic hepatitis B and C: Basic science to clinical applications. World Scientific, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), ed. Chronic Hepatitis C, Current Disease Management, March 2003. s.n., 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1944-, Gerlich W. H., ed. Research in chronic viral hepatitis. Springer-Verlag, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mattsson, Lars. Chronic non-A, non-B hepatitis: With special reference to the transfusion-associated form. Distributed by the Almqvist & Wiksell, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Chronic Hepatitis C (CHC)"

1

Cobb, Bryan R., and Alexandra Valsamakis. "Chronic Hepatitis B, C, and D." In Diagnostic Microbiology of the Immunocompromised Host. ASM Press, 2016. http://dx.doi.org/10.1128/9781555819040.ch3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bell, Beth P. "Hepatitis C Virus and Chronic Liver Disease." In Emerging Infections 6. ASM Press, 2014. http://dx.doi.org/10.1128/9781555816995.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Shan. "MODELING CHRONIC HEPATITIS C DURING RAPID THERAPEUTIC ADVANCE." In Decision Analytics and Optimization in Disease Prevention and Treatment. John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118960158.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Athwal, Varinder, and Martin Prince. "Chronic Hepatitis C." In In Clinical Practice. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43126-0_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Trabut, Jean Baptiste. "Chronic Hepatitis C." In Encyclopedia of Quality of Life and Well-Being Research. Springer Netherlands, 2014. http://dx.doi.org/10.1007/978-94-007-0753-5_365.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cohen, Stanley Martin. "Chronic Hepatitis C." In Liver Disease. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-98506-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tunney, Ruth, Martin Prince, and Varinder Athwal. "Chronic Hepatitis C." In In Clinical Practice. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-10012-3_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Trabut, Jean Baptiste. "Chronic Hepatitis C." In Encyclopedia of Quality of Life and Well-Being Research. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-17299-1_365.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bergasa, Nora V. "Chronic Hepatitis C." In Clinical Cases in Hepatology. Springer London, 2021. http://dx.doi.org/10.1007/978-1-4471-4715-2_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Arends, Joop E., Maria Cristina Leoni, and Dominique Salmon-Ceron. "Acute Hepatitis C." In Viral Hepatitis: Chronic Hepatitis C. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Chronic Hepatitis C (CHC)"

1

Sapronov, Georgy Vitalievich, and Natalia Mikhailovna Belyaeva. "POSSIBILITIES OF CORRECTING INTERFERON-INDUCED LEUKOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C." In Themed collection of papers from Foreign intemational scientific conference «Joint innovation - joint development». Medical sciences . Part 2. Ьу НNRI «National development» in cooperation with PS of UA. June 2023. Crossref, 2023. http://dx.doi.org/10.37539/230629.2023.74.73.021.

Full text
Abstract:
Objective. To determine whether leukopenia might be corrected with allokin-alpha in patients with chronic hepatitis C (CHC) receiving combination antiviral therapy (AVT). Subjects and methods. Sixty-five patients aged 18 to 36 years with CHC and leukopenia resulting from combination therapy with pegylated interferon IFN-α-2а and ribavirin were followed up. For correction of evolving IFN-induced leukopenia, the patients received 18 allokin-alpha injections subcutaneously as three subsequent courses (6 injections for each course) in a dose of 1.0 mg thrice weekly for 2 weeks at a one-week interval between the courses. The drug was administered after 12-week combination therapy. Results. The use of allokin-alpha during standard AVT for CHC leads to the elimination of IFN-induced leukopenia in 75% of the patients, which allows the whole course of therapy to be performed in the majority of patients, without reducing the dose of IFN.
APA, Harvard, Vancouver, ISO, and other styles
2

Borisov, Valery Alexandrovich, Boris Ivanovich Sanin, Svetlana Evgenievna Samsonova, Nikolaevna Harutyunyan Elena, and Borisovna Golubeva Dina. "THE EXPERIENCE OF DOMESTIC ANTIVIRAL AGENTS, AND SOME OF OWN APPROACHES IN THE TREATMENT OF CHRONIC HEPATITIS C IN ADULTS." In Themed collection of papers from Foreign intemational scientific conference «Joint innovation - joint development». Medical sciences . Part 2. Ьу НNRI «National development» in cooperation with PS of UA. June 2023. Crossref, 2023. http://dx.doi.org/10.37539/230629.2023.19.61.022.

Full text
Abstract:
In the management of 148 adult patients with chronic hepatitis C (CHC) of both sexes without special selection (taken into account only absolute contraindications to its performance) there were used domestic basic antiviral drugs - BAD| (short-living interferons (IFN) α, interferon inducers and nucleoside analogues) in parallel with additional antiviral drugs (drug glycyrrhizinic acid or amantadine) and maintenance therapy (stimulators of T-cell immunity and means of correction of side effects). Treatment was carried out in the framework of the developed complex of principles and approaches including in part, the formation of the starting average weekly dose of interferon IFN with accounting of the character of interferon status of the patient, a gradual increase in the average weekly dose of interferon IFN during the course of therapy, the delayed use of nucleoside analogs and others. As a result, against the background of a significant reduction in financial expenses and the aggressiveness of treatment the stable positive therapeutic outcome in the general population of patients occurred in 92.6%, with 87.2% in patients with genotype (G) 1.
APA, Harvard, Vancouver, ISO, and other styles
3

Jonas, Maureen, Rene Romero, Etienne Sokal, et al. "IDDF2020-ABS-0059 Safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) in pediatric patients 6 to < 18 years old with chronic hepatitis C (CHC) infection." In Abstracts of the International Digestive Disease Forum (IDDF), 22–23 November 2020, Hong Kong. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-iddf.142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Prasetia Nurwidda, Arvi Dian, Poernomo Boedi Setiawan, Iswan Abbas Nusi, et al. "Thrombocytopenia in Chronic Hepatitis C." In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007340404460452.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kchir, H., D. KAFFEL, H. Dabbebi, et al. "AB1049 Rheumatological manifestations during chronic hepatitis c." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5886.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nevkhoroshev, Yevhen, and Deonis Tkemaladze. "AUTOIMMUNE THYROIDITIS IN PATIENTS WITH CHRONIC HEPATITIS C." In TENDANCES SCIENTIFIQUES DE LA RECHERCHE FONDAMENTALE ET APPLIQUÉE, chair Lilia Bobro. European Scientific Platform, 2020. http://dx.doi.org/10.36074/30.10.2020.v2.07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Secrum microRNA-122 with HCC in chronic hepatitis C." In 2018 International Conference on Medicine, Biology, Materials and Manufacturing. Francis Academic Press, 2018. http://dx.doi.org/10.25236/icmbmm.2018.63.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

hela, KCHIR, Ons Gharbi, Dhilel Issaoui, et al. "AB0529 SICCA SYNDROME DURING CHRONIC HEPATITIS C: PREVALENCE AND CHARACTERISTICS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7584.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schlevogt, B., K. Böker, S. Mauss, et al. "Weight gain after interferon-free clearance of chronic hepatitis C – Results from the German Hepatitis C-Registry (DHC-R)." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Azzouzi, Driss, Saber Hmimass, Mohamed Borahma, et al. "P317 The hepatitis viral C and chronic inflammatory bowel disease association." In BSG LIVE’24, 17-20 June 2024, ICC Birmingham. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2024. http://dx.doi.org/10.1136/gutjnl-2024-bsg.399.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Chronic Hepatitis C (CHC)"

1

Talal, Andrew, Marianthi Markatou, Ponni Perumalswami, et al. Facilitated Telemedicine for Underserved Populations: Management of Chronic Hepatitis C Virus Infection. The TEAM-C Study. Patient-Centered Outcomes Research Institute (PCORI), 2025. https://doi.org/10.25302/04.2025.ihs.150731640.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kancheva, Lyudmila, Petar Nikolov, Tsvetelina Velikova, Ivan Valkov, Rossen Nikolov, and Lyudmila Mateva. Soluble CD14 is Associated with Disease Activity and Severity in Chronic Viral Hepatitis C and B. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, 2018. http://dx.doi.org/10.7546/crabs.2018.06.17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin, and Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.

Full text
Abstract:
Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplementary Concept] ) OR ((lipoprotein cholesterol) OR ("lipidemia") OR (lipid metabolism) OR (lipid)). Information sources: We conducted a comprehensive literature search of PubMed, Cochrane Library, Embase, and Ovid MEDLINE electronic databases from their inception to May 20, 2022.
APA, Harvard, Vancouver, ISO, and other styles
4

Evon, Donna, Jipcy Amador, Paul Stewart, et al. Changes in Health for Patients Who Complete Treatment for Chronic Hepatitis C Virus -- The PROP up TARGET Study. Patient-Centered Outcomes Research Institute® (PCORI), 2020. http://dx.doi.org/10.25302/06.2020.cer.140820660.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tangkijvanith, Pisit. Prevalence and Clinical Significance of Hepatitis B Viral Genotypes and Mutations. Faculty of Medicine, Chulalongkorn University, 2006. https://doi.org/10.58837/chula.res.2006.24.

Full text
Abstract:
Hepatitis B virus (HBV) infection is a major public health problem, with more than 400 million HBV carriers estimated worldwide. Chronic HBV infection is associated with a diverse clinical spectrum of liver damage ranging from asymptomatic carrier status, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). There have been increasing lines of evidence to indicate influences of HBV genotypes and mutations on the outcome of liver disease, particularly the development of HCC. The project is aimed to study the prevalence and clinical significance of genotypes and mutations in Precore/core and X regions of HBV in Thai patients. Our study demonstrate that genotype C and B were the predominant strains, accounting for approximately 75 and 20% of patients, respectively. Patients with HBV genotype C, compared to those with genotype B, had a higher positive rate of HBeAg and exhibited earlier progression of cirrhosis and HCC. However, there was no difference in the risk of developing HCC and its prognosis between patients with genotypes B and C. Furthermore, certain X gene mutations and, particularly, CP mutations in young patients may contribute to the development of HCC As the genetic variability of HBV differs geographically and the data available in Thailand are still limited, our study will provide useful information regarding the epidemiology and clinical relevance of HBV genotypes and mutations in Thai populations.
APA, Harvard, Vancouver, ISO, and other styles
6

Xu, Yan, Yuyang Zhao, Yong Wang, et al. Concurrent hepatic steatosis increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B or C virus infection: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.7.0099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Chronic Hepatitis C (CHC)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography